February 28, 2017 / 1:16 PM / 7 months ago

BUZZ-Valeant Pharmaceuticals: Down after Q4 revenue slump

** Canadian drugmaker’s U.S.-listed shares slide 5 pct to $15.85 in heavy premarket trade

** Posts about 13 pct fall in Q4 revenue - its third straight quarter of a double-digit percentage decrease - as sales decline across businesses and realized prices fall

** Q4 report likely to add pressure on VRX as CEO Joseph Papa tries to rebuild the business and regain investor confidence following scrutiny of its pricing and accounting practices

** However, Q4 profit beats estimates as selling, general and administrative costs fall 10.5 pct

** Up to Monday’s close, stock had risen 15 pct YTD

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below